Sunitinib

證據等級: L5

預測適應症: 10 個

Sunitinib: From Renal Cell Carcinoma to Liposarcoma

One-Sentence Summary

Sunitinib is a multi-targeted tyrosine kinase inhibitor already established as first-line therapy for advanced/metastatic renal cell carcinoma (RCC), and is also used in GIST and pancreatic neuroendocrine tumors. The TxGNN model predicts it may also be effective for Liposarcoma, with 3 clinical trials (2 graded highly relevant) and 9 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Renal cell carcinoma (established/approved indication; sunitinib is also a standard therapy for GIST and pancreatic neuroendocrine tumor)
Predicted New Indication	Liposarcoma
TxGNN Prediction Score	99.87%
Evidence Level	L2
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available directly from DrugBank in this evidence pack (flagged as a High-severity data gap). Based on the mechanistic evidence gathered for this prediction, sunitinib is a multi-targeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR1/2/3, PDGFRα/β, KIT, FLT3, and RET. Its established efficacy in renal cell carcinoma, GIST, and pancreatic neuroendocrine tumors is driven by blocking tumor angiogenesis (VEGFR) and receptor-tyrosine-kinase-driven proliferation (KIT/PDGFR).

Liposarcoma — particularly the myxoid/round cell subtype — is a highly vascularized soft tissue sarcoma with partial PDGFR pathway activation, which provides a plausible mechanistic bridge from sunitinib's original renal/GI indications to this new tumor type. This rationale is reinforced by two completed Phase II soft tissue sarcoma trials (NCT00400569, NCT00474994) that specifically enrolled liposarcoma patients, along with a dedicated Phase II study (PMID 21154746) evaluating sunitinib across leiomyosarcoma, liposarcoma, and malignant fibrous histiocytoma histologies.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00400569	Phase 2	Completed	48	Open-label single-site trial of sunitinib malate in metastatic/unresectable soft tissue sarcoma, including leiomyosarcoma, liposarcoma, fibrosarcoma, and MFH; dosed once daily 28/42-day cycles until progression or toxicity
NCT00474994	Phase 2	Completed	53	Multicenter continuous-dosing study of sunitinib in non-GIST sarcomas, explicitly covering liposarcoma population
NCT02048371	Phase 2	Completed	131	SARC024 blanket protocol primarily testing regorafenib (same TKI class) across sarcoma subtypes; sunitinib referenced only as precedent, not directly tested

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21154746	2011	Phase II trial	Int J Cancer	Phase II study of sunitinib malate in relapsed/refractory soft tissue sarcoma, focused on leiomyosarcoma, liposarcoma, and MFH; evaluated safety and efficacy across these histologies
38254762	2024	Review	Cancers	Reviews genetic, epigenetic, and transcriptomic alterations in liposarcoma to guide targeted therapy selection
24555529	2014	Review	Expert Rev Anticancer Ther	Reviews emerging systemic therapies for adult soft tissue sarcoma by subtype
22987955	2012	Review	Ann Oncol	Discusses histology-driven medical treatment of soft tissue sarcoma, noting high drug activity in myxoid liposarcoma
23482782	2013	Case report	Anticancer Res	Long-lasting clinical benefit of sunitinib malate in a heavily pre-treated metastatic liposarcoma patient
24712007	2014	Review	Magyar Onkologia	Discusses histological subtype-based medical treatment strategies for soft tissue sarcomas
28423517	2017	Genomic case series	Oncotarget	NGS profiling of extraskeletal myxoid chondrosarcoma, evaluating predictive factors for sunitinib benefit
38717131	2024	Case series	Am J Surg Pathol	Clinicopathologic analysis of a distinctive myofibroblastic sarcoma subtype; tangential relevance to sarcoma classification landscape
25884155	2015	Trial protocol	BMC Cancer	REGOSARC trial protocol evaluating regorafenib (same TKI class) in advanced soft tissue sarcoma

Norway Market Information

Sunitinib is currently not marketed in Norway — no authorizations are registered in this evidence pack (0 licenses).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-targeted tyrosine kinase inhibitor; not a conventional cytotoxic chemotherapy agent)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Based on known TKI-class effects reflected in the broader sunitinib literature (e.g., cardiac function and hypertension studies), monitoring of blood pressure, cardiac function, CBC, liver function, and thyroid function should be considered
Handling Protection	Please refer to institutional protocols for oral targeted anticancer agent handling

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase II trials and a dedicated liposarcoma-focused study provide moderate (L2) clinical evidence, and the TxGNN score is very high (99.87%). However, sunitinib is not currently marketed in Norway, and both the TFDA/Norway package insert (Blocking gap) and detailed DrugBank MOA data (High-severity gap) are missing, preventing a full safety (S1) evaluation.

To proceed, the following is needed:

Norway/TFDA-equivalent package insert (warnings, contraindications) — currently a blocking data gap
Verified DrugBank mechanism-of-action data
Norway market access assessment, given 0 current authorizations
Liposarcoma-subtype-specific (myxoid/round cell vs. dedifferentiated) efficacy stratification, as current trials pool multiple sarcoma histologies
Safety monitoring plan for hypertension and cardiac toxicity, known TKI-class risks noted in the broader sunitinib literature
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.